Immunocore Holdings PLC (IMCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Total Revenue: $310 million for the full year 2024, representing a 30% year-on-year growth.
Q4 Revenue: $84.1 million, a 5% increase from the prior quarter.
KIMMTRAK Revenue: $310 million in net revenues for 2024, with $226 million from the United States, growing at 34% year-on-year.
Cash Position: $820 million in cash and marketable securities at the end of 2024.
R&D Expenses: Increased due to investments in three Phase 3 trials and Phase 1/2 expansions in ovarian and lung cancer.
SG&A Expenses: Increased slightly due to general business functions needed to support operations.
Warning! GuruFocus has detected 3 Warning Signs with IMCR.
Release Date: February 26, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Immunocore Holdings PLC (NASDAQ:IMCR) reported a 30% year-on-year revenue growth, reaching $310 million in 2024.
KIMMTRAK sales showed strong performance with a 5% increase in Q4 compared to Q3, and a 34% year-on-year growth in the US.
The company has advanced its clinical pipeline with three ongoing Phase 3 trials and initiated two Phase 1 trials in 2024.
KIMMTRAK has been launched in 24 countries, with recent approvals in Brazil, and has achieved over 80% market share in HLA-A*02:01 positive patients.
Immunocore's R&D efforts have expanded into new therapeutic areas, including autoimmune diseases, with promising candidates targeting Type 1 diabetes and atopic dermatitis.
The reimbursement environment in Europe remains challenging, affecting revenue recognition and price negotiations.
SG&A and R&D expenses have increased compared to 2023, primarily due to investments in clinical trials and business operations.
The company faces uncertainties in achieving viral control in its HIV program, as no therapy has reliably demonstrated this yet.
There is a need for further data to confirm the efficacy and safety of new treatments in infectious diseases and autoimmune settings.
Market penetration for KIMMTRAK in the US is at 65%, indicating limited headroom for growth in this market.
Q: Can you provide details on the upcoming HIV results and what would be considered a good rate of patients not experiencing viral rebound? A: David Berman, Head of Research and Development, explained that all patients will have been off therapy to assess antiviral activity and viral reservoir reduction. He noted that this is a Phase 1 dose escalation with small cohorts, so specific rates are not the focus at this stage. The target product profile aims for suppression of viral copies to less than 200 copies per ml for two years in about 20% to 30% of people.
Q: What factors will determine the go-forward dose for the HIV program, and what are the next steps after dose escalation? A: David Berman stated that safety and evidence of antiviral activity are key factors. The current focus is on dose optimization, and there might be two doses taken forward. After confirming the signal, a randomized Phase 2 trial with a placebo is typically the next step, although recent meta-analysis suggests single-arm trials might be sufficient.
Q: Regarding the HIV program, is 12 weeks of ART interruption enough to have confidence in long-term control? A: David Berman mentioned that 12 weeks is used to gauge initial activity, as historical control rates at this point are about 1%. Longer-term control would be assessed in expansion phases, and the target product profile for commercial success is still being defined.
Q: Can you provide an update on the current efforts to generate data in ovarian and lung cancers with Brene? A: David Berman highlighted that in ovarian cancer, they are expanding studies in platinum-resistant and sensitive settings. In lung cancer, they are in the signal detection phase with combinations. Data will be shared once a comprehensive understanding is achieved, likely in the next 12 to 18 months.
Q: How are you thinking about business development opportunities for 2025? A: Travis Coy, Non-Executive Independent Director, stated that while they are excited about their current pipeline, they continuously look for opportunities that strategically fit and leverage their expertise. They are in a strong position but remain open to partnerships.
Q: What is the potential for KIMMTRAK's market share in the US, and how is treatment duration trending? A: Ralph Torbay, Senior Vice President, noted that KIMMTRAK has 65% market penetration in the US, with significant growth in community settings. The duration of therapy is performing better than in clinical trials, but it's difficult to predict where it will land long-term.
Q: Are there reimbursement challenges in Europe for KIMMTRAK, and do you anticipate similar challenges for Brene? A: Bahija Jallal, CEO, acknowledged challenges in Europe but highlighted successful negotiations and approvals. Ralph Torbay added that the reimbursement landscape is challenging for all companies, but they expect good data to facilitate access.
Q: What preclinical data supports the HIV program's potential for viral control? A: David Berman shared that preclinical studies have shown the molecule can redirect T cells to kill HIV-infected cells, even without activating the T cell. The technology can target cells with low expression, supporting its potential effectiveness.
Q: How are you thinking about the applicability of the autoimmune program to oncology? A: David Berman explained that both programs share tissue targeting technology, but differ in their effector mechanismsoncology activates T cells, while autoimmune turns them off. The programs leverage similar preclinical toxicology strategies.
Q: What are the expectations for the upcoming HIV data, and what doses will be shown? A: David Berman stated that they will present data from three doses with five to six people per dose. Success would be indicated by signals of activity, such as reservoir reduction and altered viral kinetics, which would guide further trials.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
MSTR Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds MicroStrategy Incorporated d/b/a Strategy (MSTR) Shareholders of Deadline in Securities Fraud Class Action Lawsuit
RADNOR, PA - June 21, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that a securities class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy ('Strategy') ( NASDAQ: MSTR ) on behalf of those who purchased or otherwise acquired Strategy securities between April 30, 2024, and April 4, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is July 15, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Strategy losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Strategy's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the anticipated profitability of Strategy's bitcoin-focused investment strategy and treasury operations was overstated; (2) the various risks associated with bitcoin's volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. THE LEAD PLAINTIFF PROCESS: Strategy investors may, no later than July 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Strategy investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. View the original release on
CNBC
2 hours ago
- CNBC
The Israel-Iran conflict and the other big thing that drove the stock market this week
It's been a tense and dynamic week for the world at large. The market action on Wall Street over the past four sessions was been anything but that. For the week, the S & P 500 lost 0.15%, the tech-heavy Nasdaq ticked up 0.21%, and the Dow Jones Industrial Average was basically flat, up a mere 0.02%. Beneath the surface, though, there was plenty of news for investors to digest. Here's a closer look at the biggest market themes during the holiday-shortened trading week. 1. Geopolitics: The major news story was — and still is — the intensifying war between Israel and Iran. The big question on everyone's mind is whether the U.S. will get involved. As of Friday, reports indicate that while President Donald Trump is actively reviewing options to attack Iran, nothing has been authorized. The White House has said Trump he will make a decision in the "next two weeks". As a result of the Israel-Iran conflict, investors spent the week keeping an extra close eye on the movement in safe-haven assets like gold and the dollar, as well as risk assets such as oil. Gold prices pulled back this week after their initial spike last Friday, which is when Israel's first attack on Iranian nuclear infrastructure jolted markets. The U.S. dollar index , meanwhile, strengthened this week but still remains near multiyear lows. Oil rose again for the week, with international benchmark Brent crude climbing nearly 4%. For those looking to gauge what the market thinks will happen with Iran, look to oil. The commodity is currently acting as something of proxy on the odds of the conflict intensifying and America directly entering the fray. 2. Fed updates: The other big theme of the week centered on the health of the U.S. economy in the lead up to Wednesday afternoon, when we got the Federal Reserve's latest interest rate decision and revised economic projections. Ultimately, the Fed kept its benchmark lending rate unchanged on Wednesday following its two-day policy meeting. The decision followed lackluster updates on the state of the consumer and the housing market , along with lower-than-expected inflation readings the week prior. As we outlined earlier this week , the Fed is in a tough spot when it comes to abiding by its dual mandate of ensuring price stability and low unemployment. The state of play requires nuance. On the one hand, there is evidence in support of rate cuts, namely some cracks in the consumer — even if the consumer has remained largely and impressively resilient — and the Fed's own updated outlook for lower real GDP growth and higher unemployment this year. On the other hand, the Fed is now expecting higher inflation this year than it did in March, which would support the need for higher interest rates. Given these dueling dynamics and the uncertainty around tariff impacts, the central bank's decision to keep interest rates steady makes sense. While the Fed certainly doesn't want to wait too long and make the same mistake we saw coming out of the Covid-19 pandemic, we must acknowledge that the causes of a potential rebound in inflation are different this time around. Tariffs will likely push up prices, but that may be a one-time increase, as opposed to the sustained inflation we saw exiting the pandemic, which was driven by massive supply chain disruptions and shifts in consumer behavior. As a result, we believe the apparent bias to be more worried about the job market and overall economic growth — and therefore cut rates later this year — makes sense, too. Indeed, the Fed's updated projections still pencil in two rate cuts in 2025, the same as in March despite the aforementioned revisions to its inflation and growth outlook. Fed Governor Christopher Waller made the case Friday that the cuts should start as early as July, arguing that the inflation risk posed by tariffs is not significant and ensuring resiliency in the labor market should be a higher priority. Waller's argument is basically that it's better to move now than wait for a jump in unemployment. Our biggest focus at the Club is staying nimble, given the highly volatile nature of geopolitics at the moment. No doubt, rate decisions are important to think about, but they're only one small part of the investing puzzle to navigate each day. For this reason, we continue to focus more on individual company fundamentals and industry trends rather than higher-level dynamics, important as they are to shaping our worldview. Cybersecurity stocks are one example that we highlighted this week. Another example would be the news we got from Club names Meta Platforms and Amazon this week on their artificial intelligence efforts. We think the implications that AI will have on the cost structures, revenue opportunities and efficiency gains should weigh far more heavily in the minds' of long-term investors than whether the Fed will cut in July or September. (Jim Cramer's Charitable Trust is long META, AMZN. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Yahoo
2 hours ago
- Yahoo
1 Soaring Growth Stock to Buy Hand Over Fist Before It Is Too Late
Applied Materials stock is in rebound mode. Even better, it still trades at an attractive valuation. The semiconductor equipment supplier expects stronger growth in the future due to increased spending by chipmakers and foundries. Applied Materials stock could deliver terrific gains going forward thanks to favorable end-market developments. 10 stocks we like better than Applied Materials › Share prices of Applied Materials (NASDAQ: AMAT) have jumped impressively from the 52-week lows they hit just over two months ago, gaining 31% in a short time on the back of the broader rally in the tech-laden Nasdaq Composite index that has clocked solid gains of 25% during the same period. What's worth noting is that investors shrugged off Applied Materials' mixed fiscal 2025 second-quarter results (for the three months ended April 27), which were released on May 15. The semiconductor equipment supplier reported robust growth in sales and earnings for the quarter, but its top line was a tad lighter than expected. The company's outlook for the current quarter followed a similar pattern. However, savvy investors would do well to note that Applied Materials' results and guidance were resilient at a time when the tariff-fueled turmoil and the restrictions on sales of semiconductor equipment to China are turning out to be headwinds for the company. Let's take a look at the factors that could help Applied Materials stock maintain its momentum on the market. Applied Materials reported year-over-year growth of 7% in its revenue in the previous quarter, while its non-GAAP earnings per share (EPS) increased at a faster pace of 14%. A quarter of its revenue came from sales of semiconductor manufacturing equipment to China. For comparison, Applied Materials' top-line growth was flat in the same quarter last year, while its adjusted earnings increased at a much slower pace of 5%. Applied Materials got 43% of its revenue from Chinese customers in the year-ago period. So, the company's growth accelerated even though restrictions on sales of advanced chipmaking equipment to Chinese customers hurt its business in its largest market abroad. This can be attributed to the global growth in semiconductor demand owing to catalysts such as artificial intelligence (AI). Equity research firm Summit Insights Group predicts that the improvement in demand for advanced chips in the second half of 2025 and next year should allow Applied Materials to continue doing well even if its Chinese business remains negatively impacted. Applied Materials CEO Gary Dickerson's remarks on last month's earnings conference call suggest something similar: The impact of AI datacenter innovation and investments is apparent in the wafer fab equipment market, where there are significant shifts in the spending mix this year. We see investment in leading edge foundry-logic growing substantially in 2025, and we also expect spending for leading-edge DRAM to be up significantly. Large-scale AI infrastructure investments such as the $500 billion Stargate project and the multibillion-dollar investments by cloud-computing giants to bolster their AI capabilities are the reasons why foundries and chipmakers are focused on enhancing their manufacturing capacities. Foundry giant Taiwan Semiconductor Manufacturing (NYSE: TSM), for instance, is set to increase its capital expenditures (capex) by 38% at the midpoint of its forecast to $40 billion in 2025. The Taiwan-based company is on track to build nine fabrication plants this year. TSMC further points out that it will spend 70% of its capital spending on advanced process nodes. That's not surprising as almost three-fourths of the company's revenue comes from selling chips manufactured using advanced nodes that are 7-nanometer (nm) or smaller in size. Looking ahead, TSMC estimates that its revenue from sales of AI chips is likely to increase at an annual rate of mid-40% through 2029. So, it won't be surprising to see the company spending more money on shoring up the production capacity of advanced chips to meet the AI-fueled demand. The increase in capex by the likes of TSMC is expected to drive a 2% increase in global semiconductor equipment spending this year to $110 billion, followed by a much stronger increase of 18% in 2026. This should ideally lead to an acceleration in Applied Materials' growth as well, paving the way for more stock price upside. Analysts are forecasting a 10% increase in Applied Materials' earnings this fiscal year to $9.49 per share. This is expected to be followed by a smaller jump in fiscal 2026 before another year of double-digit growth in fiscal 2027. However, the sharp acceleration in global semiconductor equipment spending could allow Applied Materials to grow at a faster rate over the next couple of years. But even if the company's bottom line grows in line with consensus expectations and its earnings hit $11.17 per share after a couple of fiscal years (as per the chart above), its stock price could jump to $329 (based on the tech-laden Nasdaq-100 index's forward earnings multiple of 29). That points toward an 88% gain from current levels in the next three years. Applied Materials stock is now trading at just 18 times forward earnings, which is a nice discount to the Nasdaq-100 index, which serves as a proxy for tech stocks. However, the market could reward Applied Materials with a richer earnings multiple in the future if it can deliver stronger-than-expected earnings growth. That's why savvy investors may want to buy this semiconductor stock while it is still trading at an incredibly cheap valuation, as it has the ability to go on a terrific bull run going forward. Before you buy stock in Applied Materials, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Applied Materials wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Applied Materials and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy. 1 Soaring Growth Stock to Buy Hand Over Fist Before It Is Too Late was originally published by The Motley Fool Sign in to access your portfolio
